Jaguar Health, Inc.

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			After hours 06:29:58 am
1.430 ^USD	+87.05%		1.065	-25.52%

16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI

Gastrointestinal drugmaker Jaguar Health's Q3 net loss narrows

Published on 11/17/2025 at 06:47 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Jaguar Health, Inc.

16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI
24/11	Jaguar Health, Inc. announced that it has received $10.81 million in funding	CI
21/11	Sector Update: Health Care Stocks Softer Late Afternoon	MT
21/11	Sector Update: Health Care	MT
21/11	Jaguar Health's Napo Pharmaceuticals Submits Amended Crofelemer Trial Protocol to FDA	MT
17/11	Jaguar Health, Inc., Q3 2025 Earnings Call, Nov 17, 2025
17/11	Gastrointestinal drugmaker Jaguar Health's Q3 net loss narrows	RE
15/11	Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/11	Jaguar Health, Inc. announced that it expects to receive $10.81 million in funding	CI
10/25/10	Jaguar Health, Inc. announced that it has received $0.999951 million in funding from Brown Stone Capital, LTD	CI
04/25/04	Jaguar Health files for resale of up to 2.6 million shares by selling stockholders - SEC filing	RE
02/25/02	Jaguar Health says on September 28 entered securities purchase agreement with Brown Stone Capital Limited - SEC filing	RE
28/25/28	Jaguar Health, Inc. announced that it expects to receive $0.999951 million in funding from Brown Stone Capital, LTD	CI
24/25/24	Jaguar Health Unit Submits Orphan Drug Status Application to US FDA for Cancer Therapy-Related Diarrhea Drug	MT
10/25/10	Jaguar Health, Inc. announced that it has received $2.380001 million in funding	CI
09/25/09	Jaguar Health, Inc. announced that it expects to receive $2.380001 million in funding	CI
15/25/15	Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/25/14	Jaguar Health enters sixth ATM amendment with Ladenburg and Lucid	RE
14/25/14	Jaguar Health, Inc., Q2 2025 Earnings Call, Aug 14, 2025
25/25/25	Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment	MT
11/25/11	Jaguar Health Establishes First Site for Canalevia-CA1 Field Study	MT
21/25/21	Jaguar Health Prices Offering of Shares, Warrants	MT
16/25/16	Jaguar Health, Inc., Q1 2025 Earnings Call, May 15, 2025
15/25/15	Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Employees

Sector

Pharmaceuticals

Calendar

06/04 - Q4 2025 Earnings Release (Projected)

More about the company